

DAFTAR PUSTAKA

1. Sitorus MF, Amalia L. Hubungan antara Penggunaan Antihipertensi pada Pasien Preeklamsia terhadap Insidensi Asfiksia Neonatal dan Berat Badan Lahir Rendah di RSUP Dr. Hasan Sadikin Bandung. *Indones J Clin Pharm.* 2020;9(4):280.
2. Nurmainah N, Hadad FM, Andrie M. Profil Proteinuria dan Tekanan Darah pada Pasien Preeklamsia Berat yang menggunakan Antihipertensi. *Indones J Clin Pharm.* 2021;10(2):79.
3. Yang Y, Le Ray I, Zhu J, Zhang J, Hua J, Reilly M. Preeclampsia Prevalence, Risk Factors, and Pregnancy Outcomes in Sweden and China. *JAMA Netw Open.* 2021;4(5):1–14.
4. WHO. Maternal and reproductive health [Internet]. 2022. Available from: reproductive health
5. Badan Penelitian dan Pengembangan Kesehatan. Laporan Nasional Riskesdas 2018. In Jakarta: Badan Penelitian dan Pengembangan Kesehatan; 2018.
6. Permatasary O. Faktor-Faktor Yang Berhubungan Dengan Kejadian Preeklamsi Berat Di Rsup Dr. M. Djamil Padang Tahun 2018. Universitas Andalas; 2018.
7. Arpaci H, Koban Y, Tok A, Beyoğlu A. Ocular perfusion pressure and intraocular pressure in pregnant women with severe preeclampsia. *Ginekol Pol.* 2018;89(9):513–7.
8. Gustri Y, Rico Januar Sitorus FU. Determinan Kejadian Preeklampsia pada Ibu Hamil. *J Midwifery Jur Kebidanan Politek Kesehat Gorontalo.* 2021;7(1):31.
9. Andriani C, Lipoeto NI, Utama BI. Hubungan Indeks Massa Tubuh dengan Kejadian. 2013;5(1):173–8.
10. POGI. Diagnosis dan Tata Laksana Pre-Eklampsia. 2016.
11. Özkara A, Kaya AE, Başbuğ A, Ökten SB, Doğan O, Çağlar M, et al. Proteinuria in preeclampsia: Is it important? *Ginekol Pol.* 2018;89(5):256–61.
12. Setyawan JFD, Wiryanthini IAD, Tianing NW. Gambaran Kadar Protein Urine pada Ibu Hamil Preeklampsia dan Eklampsia di RSUP Sanglah Denpasar Tahun 2017. *J Med Udayana [Internet].* 2019;8(12):1–5. Available from: <https://ojs.unud.ac.id>
13. Situmorang T., Darmantalm Y, Januarista A, Sukri. Faktor - Faktor Yang Berhubungan Dengan Kejadian Rsu Anutapura Palu. *J Kesehat Tadulako [Internet].* 2016;2(1):1–75. Available from:

<http://jurnal.fk.untad.ac.id/index.php/htj/article/view/21>

14. Fatkhiyah N, Kodijah K, Masturoh M. Determinan Maternal Kejadian Preeklampsia: Studi Kasus di kabupaten Tegal, Jawa Tengah. *J Keperawatan Soedirman*. 2018;11(1):53.
15. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *JAMA - J Am Med Assoc*. 2014;311(5):507–20.
16. Arbor A. NHBPEP Report on High Blood Pressure in Pregnancy : A Summary. *Aafp*. 2001;64(2):263–70.
17. Legawati, Utama NR. Analisis Faktor Risiko Kejadian Preeklampsia Berat di RSUD Rujukan Kabupaten dan Provinsi Kalimantan Tengah.
18. Kemenkes. Profil Kesehatan Indonesia Tahun 2015. Jakarta: Kementerian Kesehatan Republik Indonesia; 2016.
19. Auger N, Fraser WD, Healy-Profítós J, Arbour L. Association between preeclampsia and congenital heart defects. *JAMA - J Am Med Assoc*. 2015;314(15):1588–98.
20. Laneloh DC. Preeklampsia Berat dan Eklampsia : Tatalaksana Anestesia Perioperatif. Yogyakarta: Deepublish; 2018.
21. Prawirohardjo S. Ilmu Kebidanan. Jakarta: PT Bina Pustaka Sarwono Prawirohardjo; 2014.
22. Ayu N. Patologi dan Patofisiologi Kebidanan. Yogyakarta: Nuha Medika; 2016.
23. Madazli R, Yuksel MA, Imamoglu M, Tuten A, Oncul M, Aydin B, et al. Comparison of clinical and perinatal outcomes in early- and late-onset preeclampsia. *Arch Gynecol Obstet*. 2014;290(1):53–7.
24. Phipps E, Prasanna D, Brima W, Jim B. Preeclampsia: Updates in pathogenesis, definitions, and guidelines. *Clin J Am Soc Nephrol*. 2016;11(6):1102–13.
25. Poon LC, Nicolaides KH. First-trimester maternal factors and biomarker screening for preeclampsia. *Prenat Diagn*. 2014;34(7):618–27.
26. Bourée P. [Risk factors for preeclampsia]. *Med Sante Trop*. 2012;22(3):263–4.
27. Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: Systematic review of controlled studies. *Br Med J*. 2005;330(7491):565–7.
28. Bartsch E, Medcalf KE, Park AL, Ray JG, Al-Rubaie ZTA, Askie LM, et al. Clinical risk factors for pre-eclampsia determined in early pregnancy: Systematic review and meta-analysis of large cohort studies. *BMJ*. 2016;353.

29. Mignini LE, Carroli G, Betran AP, Fescina R, Cuesta C, Campodonico L, et al. Interpregnancy interval and perinatal outcomes across Latin America from 1990 to 2009: A large multi-country study. *BJOG An Int J Obstet Gynaecol.* 2016;123(5):730–7.
30. Saito S, Sakai M, Sasaki Y, Nakashima A, Shiozaki A. Inadequate tolerance induction may induce pre-eclampsia. *J Reprod Immunol.* 2007;76(1–2):30–9.
31. Barton JR, Sibai BM. Prediction and prevention of recurrent preeclampsia. *Obstet Gynecol.* 2008;112(2 PART 1):359–72.
32. Prawirohardjo S. *Buku Ilmu Kebidanan Edisi 4.* Jakarta: PT Bina Pustaka Sarwono Prawirohardjo; 2016.
33. Kusnarman K. *Patomekanisme Preeklampsia Terkini_Mengungkapkan teori-teori terbaru.* Malang: Universitas Brawijaya Press; 2014.
34. Saraswati N, Mardiana M. Faktor Risiko Yang Berhubungan Dengan Kejadian Preeklampsia Pada Ibu Hamil (Studi Kasus Di Rsud Kabupaten Brebes Tahun 2014). *Unnes J Public Heal.* 2016;5(2):90.
35. Subandrate, Faisal ME, Anggraini NW. Peranan Stres Oksidatif pada Preeklampsia. *Cermin Dunia Kedokt.* 2017;44(5):353–5.
36. Tanto C. *Preeklampsia Dalam Kapita Selekta Kedokteran Edisi Keempat.* Jakarta: Media Aesculapius; 2014.
37. Kandou PRD, Hutabarat RA, Suparman E, Wagey F, Obstetri B, Kedokteran F, et al. Karakteristik pasien dengan preeklampsia Kandidat Skripsi Fakultas Kedokteran Universitas Sam Ratulangi Manado World Health Organization (WHO) memperkirakan meninggal setiap hari akibat komplikasi kehamilan, proses kelahiran, dan akibat negara dimana. *J e-Clinic.* 2016;4(1):31–5.
38. Excellence NI for H and C. Hypertension in pregnancy: diagnosis and management. *Am J Obs Gynecol [Internet].* 2010;77(1):S1-s22. Available from: [http://www.nice.org.uk/guidance/cg107%5Cnhttps://www.dovepress.com/getfile.php?fileID=7818%5Cnhttp://www.ijgo.org/article/S0020-7292\(02\)80002-9/abstract](http://www.nice.org.uk/guidance/cg107%5Cnhttps://www.dovepress.com/getfile.php?fileID=7818%5Cnhttp://www.ijgo.org/article/S0020-7292(02)80002-9/abstract)
39. Alatas H. Hipertensi pada Kehamilan. *Herb-Medicine J.* 2019;2(2):27.
40. Lelia : Duley, Shireen : Meher, Leanne : Jones. : Drugs for treatment of very high blood pressure during pregnancy SO-: Cochrane Database of Systematic Reviews YR-: 2013 NO-: 7. 2013;(7).
41. Vest AR, Cho LS. Hypertension in Pregnancy. *Cardiol Clin.* 2012;30(3):407–23.
42. Molvi SN, Mir S, Rana VS, Jabeen F, Rauoof Malik A. Role of antihypertensive therapy in mild to moderate pregnancy-induced hypertension: A prospective randomized study comparing labetalol with alpha methyldopa. *Arch Gynecol Obstet.* 2012;285(6):1553–62.

43. Magee LA, von Dadelszen P, Singer J, Lee T, Rey E, Ross S, et al. Do labetalol and methyldopa have different effects on pregnancy outcome? Analysis of data from the Control of Hypertension In Pregnancy Study (CHIPS) trial. *BJOG An Int J Obstet Gynaecol*. 2016;123(7):1143–51.
44. Whelton PK, Carey RM. The 2017 Clinical Practice Guideline for High Blood Pressure. *JAMA - J Am Med Assoc*. 2017;318(21):2073–4.
45. Kario K, Park S, Chia YC, Sukonthasarn A, Turana Y, Shin J, et al. 2020 Consensus summary on the management of hypertension in Asia from the HOPE Asia Network. *J Clin Hypertens*. 2020;22(3):351–62.
46. Podymow T, August P. Update on the use of antihypertensive drugs in pregnancy. *Hypertension*. 2008;51(4 PART 2 SUPPL.):960–9.
47. Olson-Chen C, Seligman NS. Hypertensive Emergencies in Pregnancy. *Crit Care Clin* [Internet]. 2016;32(1):29–41. Available from: <http://dx.doi.org/10.1016/j.ccc.2015.08.006>
48. Strasinger SK L. *Urinalisis dan Cairan Tubuh* (6th ed.; M. B. Mardiana, ST, Ed.). Jakarta: Penerbit Buku Kedokteran EGC; 2008.
49. H S. *Urinalisis* (1st ed.). Palembang: Multi Sarana; 2011.
50. Ardiansyah M. *Medikal Bedah Untuk Mahasiswa* (1st ed.). Yogyakarta: Diva Press Anggota IKAPI; 2012.
51. Prabu OG, Shatri H, Shpehuldq P, Phqxuxq I, Vljql V, Whukdgs NDQ, et al. Penggunaan ACE -Inhibitor untuk Mengurangi Proteinuria pada Sindrom Nefrotik. 2015;3(2).
52. Tanacan A, Fadiloglu E, Beksac MS. The importance of proteinuria in preeclampsia and its predictive role in maternal and neonatal outcomes. *Hypertens Pregnancy* [Internet]. 2019;38(2):111–8. Available from: <https://doi.org/10.1080/10641955.2019.1590718>
53. Sumampouw. Gambaran Preeklampsia Berat Dan Eklampsia Ditinjau Dari Faktor Risiko di RSUP Prof. DR. R. D. Kandou Manado. *J Med dan Rehabil*. 2019;1(3):1–5.
54. Familia TP. *Karakteristik dan Outcome Pasien Preeklampsia Berat di RSUP Dr. M. Djamil Padang Tahun 2020*. Andalas University; 2021.
55. Dewie A, Pont A V, Purwanti A. Hubungan Umur Kehamilan Dan Obesitas Ibu Hamil Dengan Kejadian Preeklampsia Di Wilayah Kerja Puskesmas Kampung Baru Kota Luwuk. 2020;10:21–7.
56. Nurizawati, Nurmainah NUP, Program. *Profil Penggunaan Antihipertensi Pada Pasien Pre-eklampsia di Rumah Sakit Umum Yarsi Pontianak Tahun 2018*. 2018;
57. Giovanna E Lombo FWWLSM. *Karakteristik Ibu Hamil Dengan Preeklampsia di RSUP Prof Dr. R. D. Kandou Manado*. *IEEE Trans Syst Man Cybern*. 1976;SMC-6(12):882–7.

58. Ema Wahyu Ningrum N. Hubungan Antara Riwayat Hipertensi Dengan Kejadian Preeklamsia Pada Ibu Bersalin Di RSUD Prof. Dr. Margono Soekardjo Purwokerto. 08.
59. Mutter WP, Karumanchi SA. Molecular mechanisms of preeclampsia. 2008;75:1–8.
60. Amore CD, Trotta F, Cas R Da, Zocchetti C, Cocci A. Antihypertensive drug use during pregnancy : a population based study. 2015;(September).
61. Togarikar SM. Efficacy of methyldopa versus nifedipine in mild and severe pregnancy induced hypertension. 2017;6(10):4544–8.
62. Shimamoto K, Ando K, Fujita T, Hasebe N, Higaki J, Horiuchi M, et al. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2014). *Hypertens Res.* 2014;37(4):253–390.
63. Yansyah A, Kusmardika DA, Ariska A. *Wellness and healthy magazine.* 2019;1(February):139–44.
64. Kalra S, Kalra B, Agrawal N. Combination therapy in hypertension : An update. 2010;1–11.
65. Carolina Guerrero-García MD AFR-GP. Combination therapy in the treatment of hypertension. 2018;1–9.
66. Sarafidis PA, Khosla N, Bakris GL. Antihypertensive Therapy in the Presence of Proteinuria. 2007;49(1):12–26.
67. Fitri F. Pengaruh Penggunaan MgSO₄ Sebagai Terapi Pencegahan Kejang Pada Preeklamsia. *J Farm Klin [Internet].* 2020;1(1):1–171. Available from: <http://etd.eprints.ums.ac.id/14871/%0Ahttps://doi.org/10.1016/j.cell.2017.12.025%0Ahttp://www.depkes.go.id/resources/download/info-terkini/hasil-risikesdas-2018.pdf%0Ahttp://www.who.int/about/licensing/%0Ahttp://jukeunila.com/wp-content/uploads/2016/12/Dea-Nur>
68. Espinoza J, Vidaeff A, Pettker christian m, Simhan H. Gestational Hypertension and Preeclampsia AJ Clinical Management Guidelines for Obstetrician – Gynecologists. *Obstet Gynecol.* 2019;133(76):168–86.